Publications by authors named "Patrick Hwu"

100Publications

Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.

J Clin Oncol 2020 Oct 30:JCO2000605. Epub 2020 Oct 30.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.00605DOI Listing
October 2020

Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer.

JAMA Netw Open 2020 Jul 1;3(7):e207911. Epub 2020 Jul 1.

Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2020.7911DOI Listing
July 2020

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.

J Hematol Oncol 2019 12 30;12(1):145. Epub 2019 Dec 30.

Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-019-0835-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937824PMC
December 2019

Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.

Cancer Immunol Immunother 2019 Nov 10;68(11):1747-1757. Epub 2019 Oct 10.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center (UT MDACC), Unit 904, 7455 Fannin, Houston, TX, 77054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02402-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269372PMC
November 2019

Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.

Cancer Immunol Immunother 2019 Sep 12;68(9):1515-1526. Epub 2019 Sep 12.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02385-xDOI Listing
September 2019

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy.

Cancer Immunol Res 2019 06 17;7(6):860-865. Epub 2019 Apr 17.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-18-0682DOI Listing
June 2019

Adjuvant Ipilimumab in High-Risk Uveal Melanoma.

Cancers (Basel) 2019 Jan 29;11(2). Epub 2019 Jan 29.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.mdpi.com/2072-6694/11/2/152
Publisher Site
http://dx.doi.org/10.3390/cancers11020152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406862PMC
January 2019

Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.

Gynecol Oncol 2018 12 24;151(3):407-413. Epub 2018 Oct 24.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183128
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.10.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281778PMC
December 2018

Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study.

Cancer Epidemiol 2018 12 19;57:80-84. Epub 2018 Oct 19.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA; California Pacific Medical Center Research Institute, San Francisco, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18777821183041
Publisher Site
http://dx.doi.org/10.1016/j.canep.2018.10.003DOI Listing
December 2018

T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Clin Cancer Res 2018 06 1;24(12):2920-2934. Epub 2018 Feb 1.

Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-1365DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004229PMC
June 2018

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Nat Rev Clin Oncol 2018 Jan 19;15(1):47-62. Epub 2017 Sep 19.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2017.148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733403PMC
January 2018

Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.

Ann Rheum Dis 2017 Dec 22;76(12):2061-2064. Epub 2017 Aug 22.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2017-21156
Publisher Site
http://dx.doi.org/10.1136/annrheumdis-2017-211560DOI Listing
December 2017

Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators.

Front Immunol 2017 16;8:689. Epub 2017 Jun 16.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2017.00689DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473350PMC
June 2017

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.

Clin Sarcoma Res 2017 15;7:11. Epub 2017 Jun 15.

Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13569-017-0077-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471883PMC
June 2017

A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.

Cancer Immunol Immunother 2017 Oct 13;66(10):1359-1366. Epub 2017 Jun 13.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-017-2030-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898971PMC
October 2017

Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.

J Neurooncol 2017 Jul 12;133(3):595-602. Epub 2017 May 12.

University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-017-2470-4DOI Listing
July 2017

Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8 T Cells and Histone Acetyltransferases.

Cancer Immunol Res 2017 04 21;5(4):300-311. Epub 2017 Feb 21.

Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-16-0234DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382872PMC
April 2017

Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination.

Oncoimmunology 2016 7;5(12):e1238539. Epub 2016 Oct 7.

Department of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1238539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214696PMC
October 2016

IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.

Cancer Immunol Res 2016 11 3;4(11):983-994. Epub 2016 Oct 3.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0195DOI Listing
November 2016

Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.

J Immunother 2017 01;40(1):11-20

Departments of *Stem Cell Transplantation and Cellular Therapy †Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China ‡Melanoma Medical Oncology §Cancer Systems Imaging ∥Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138115PMC
January 2017

Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells.

Sci Signal 2016 09 27;9(447):ra94. Epub 2016 Sep 27.

Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061503PMC
http://dx.doi.org/10.1126/scisignal.aaf3957DOI Listing
September 2016

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Cell 2016 Oct 22;167(2):397-404.e9. Epub 2016 Sep 22.

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088716PMC
http://dx.doi.org/10.1016/j.cell.2016.08.069DOI Listing
October 2016

Complementing T-cell Function: An Inhibitory Role of the Complement System in T-cell-Mediated Antitumor Immunity.

Cancer Discov 2016 09;6(9):953-5

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0698DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069599PMC
September 2016

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Mol Cancer Ther 2016 10 25;15(10):2442-2454. Epub 2016 Jul 25.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079683PMC
http://dx.doi.org/10.1158/1535-7163.MCT-15-0963DOI Listing
October 2016

Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2.

Oncotarget 2016 Jun;7(24):36074-36091

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.8683DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094984PMC
June 2016